US-based comprehensive CDMO focused on advancing next-generation cell- and tissue-based therapies, from R&D to cGMP manufacturing. Located in Arcadia, California. Has partnerships with CellVax Therapeutics (first manufacturing collaboration, Phase 2 trial for FK-PC101), Pluristyx (iPSC-derived therapies), and Insight68 (Pharma 4.0 AI software). Works with iPSC, NK cells, T cells, and CAR-T for allogeneic and autologous therapies. Expanding leadership team with experienced biopharma executives.
Cell therapy CDMO (iPSC, NK cells, T cells, CAR-T), cGMP cell manufacturing, tissue-based therapy development, analytical development for cell therapies, regulatory affairs, Pharma 4.0 integration.
1 site worldwide
No reviews available yet.
No documents available.